RISVAN Drug Patent Profile

Which patents cover Risvan, and when can generic versions of Risvan launch?

Risvan is a drug marketed by Labs Farms Rovi Sa and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and eighty-nine patent family members in thirty-six countries.

The generic ingredient in RISVAN is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Risvan

A generic version of RISVAN was approved as risperidone by RISING on October 8^th, 2008.

Summary for RISVAN

International Patents:	189
US Patents:	14
Applicants:	1
NDAs:	1
Patent Applications:	4,330
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RISVAN
What excipients (inactive ingredients) are in RISVAN?	RISVAN excipients list
DailyMed Link:	RISVAN at DailyMed

US Patents and Regulatory Information for RISVAN

RISVAN is protected by fourteen US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Labs Farms Rovi Sa	RISVAN	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	214835-002	Mar 29, 2024		DISCN	Yes	No			Y
Labs Farms Rovi Sa	RISVAN	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	214835-002	Mar 29, 2024		DISCN	Yes	No			Y
Labs Farms Rovi Sa	RISVAN	risperidone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	214835-001	Mar 29, 2024		DISCN	Yes	No

EU/EMA Drug Approvals for RISVAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Laboratorios Farmacéuticos Rovi, S.A.	Okedi	risperidone	EMEA/H/C/005406Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.	Authorised	no	no	no	2022-02-14

International Patents for RISVAN

See the table below for patents covering RISVAN around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1124369
Denmark	2879661
Mexico	362874

Supplementary Protection Certificates for RISVAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0196132	94C0008	Belgium		PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208

RISVAN Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is RISVAN?

RISVAN is the brand name for risperidone, an antipsychotic medication marketed primarily for schizophrenia, bipolar disorder, and irritability associated with autism. Approved by the U.S. Food and Drug Administration (FDA) in 1993, risperidone is classified as a second-generation antipsychotic.

Market Overview

Global Market Size

The risperidone market generated approximately $3.2 billion in 2022, with a compound annual growth rate (CAGR) of 4.1% from 2019 to 2022. Regional markets differ significantly:

Region	2022 Revenue (USD billion)	CAGR (2019-2022)
North America	1.7	3.5%
Europe	0.8	4.2%
Asia-Pacific	0.5	5.8%
Rest of World	0.2	2.9%

Key Drivers

• Increasing prevalence of schizophrenia, bipolar disorder, and autism spectrum disorder.
• Expanded indications and off-label use.
• Generic formulations lowering prices, broadening access.
• Growing awareness and diagnosis in emerging markets.

Competitive Landscape

The market features:

• Namesake brands: RISVAN (risperidone), with manufacturers such as Johnson & Johnson and Teva Pharmaceuticals.
• Multiple generics: Dominant in mature markets; accounted for nearly 70% of sales in 2022.
• New entrants: Limited, due to patent expirations and regulatory barriers.

Patent and Regulatory Developments

Risperdal’s patent expired in the U.S. in 2008. Subsequent data exclusivity and formulation patents extended some exclusivity periods, influencing market share and pricing strategies. Biosimilars and novel formulations are under development but have yet to dominate the market.

Financial Trajectory

Revenue Trends

Global revenues have shown steady but modest growth. Contributions from developed nations stabilize due to mature markets, while emerging markets drive incremental expansion.

Year	Estimated Revenue (USD billion)
2022	3.2
2021	3.1
2020	3.0

Price Dynamics

Post-patent expiry led to price erosion:

• In the US, average wholesale prices (AWP) for risperidone fell by approximately 35% between 2010 and 2020.
• Generics account for over 70% of the US risperidone market by volume, leading to price competition.

Cost Structure

• Development costs for biosimilars or new formulations exceed $100 million per product.
• Manufacturing costs are relatively low compared to R&D; active ingredients are inexpensive due to synthesis processes.

Profitability Outlook

Profit margins declined from 40% pre-patent expiry to 15-20% for generics, due to price competition. Companies investing in marketing for branded risperidone target niche indications or extended-release formulations to maintain margins.

Future Market Outlook

Growth Potential

• Market forecast predicts CAGR of 3.1% from 2023 to 2028, reaching approximately $4.3 billion.
• Expansion in emerging markets due to improved mental health awareness and increasing healthcare infrastructure.
• Adoption of long-acting injectable formulations, such as risperidone microspheres, expected to slow decline in brand-specific revenues.

Innovation and Pipeline

• No major new chemical entities (NCEs) for risperidone; focus on delivery methods.
• Extended-release injectables and combination therapies under clinical evaluation.
• Discontinuation or revision of off-label uses may impact revenue.

Regulatory and Policy Impact

• US and Europe tighten rules on off-label marketing and pricing.
• Patent protections for related formulations expire, spurring generic competition.
• Market access challenges persist in certain Asian countries due to affordability and local regulations.

Risks to Financial Trajectory

• Market saturation in developed countries limits growth.
• Pricing pressures from generics reduce profit margins.
• Regulatory hurdles for biosimilars and new formulations.
• Competition from other atypical antipsychotics (e.g., aripiprazole, olanzapine).

Key Takeaways

• The risperidone market is mature, with revenues stabilizing in developed markets and growth driven mainly by emerging regions.
• Generics dominate sales post-patent expiry, pressuring prices and margins.
• Innovation focuses on delivery systems rather than the chemical entity.
• Future growth relies on market penetration in emerging economies, new formulations, and extended-release options.
• Regulatory and pricing pressures pose ongoing challenges for profitability.

FAQs

1. How dominant is risperidone in the antipsychotic market?
It remains a leading second-generation antipsychotic, with a 15-20% share globally, but faces competition from newer agents with improved side-effect profiles.

2. What is the main revenue threat for risperidone?
Generic competition and declining prices post-patent expiration, alongside regulatory restrictions on off-label uses.

3. Are there new formulations that could revive risperidone sales?
Extended-release injectable versions and combination therapies are under development, which could stabilize or increase revenue in certain segments.

4. How significant are emerging markets for the future of risperidone?
Crucial; they represent the majority of future growth due to increasing mental health awareness, diagnosis rates, and healthcare infrastructure.

5. What are the prospects for biosimilars or alternatives to risperidone?
Limited, as risperidone is a small molecule, not a biologic; biosimilars are not applicable. However, new delivery systems may offer differentiation.

---

References

[1] MarketWatch. (2023). Global Risperidone Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Thematic Review of Antipsychotic Market Data.
[3] U.S. Food and Drug Administration. (2023). Risperidone (Risperdal) Approval and Patent Data.